ClinicalTrials.gg

Program

Voriconazole

Also written as “voriconazole”, “voriconazole (Vfend)” and “oral voriconazole”.

Its studies are mostly in Aspergillosis · Mycoses · Invasive Fungal Infections · Candidemia · Candidiasis, led by 3 companies.

Furthest: phase 4, since Aug 31, 200523 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer200 open or runningphase 4since Aug 31, 2005Aug 25, 2005none ahead
Yung Shin Pharm. Ind.20 open or runningphase 4since Sep 21, 2016Sep 21, 2016none ahead
Chong Kun Dang Pharmaceutical10 open or runningphase 1since Dec 13, 2015Dec 13, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Aug 25, 2005.

  1. Oct 19, 2007Phase 4 study in CandidemiaPfizer · NCT00548262 · 54 enrolled · Brazil, Chile, Colombia and more
  2. Nov 9, 2007Phase 2 study in PharmacokineticsPfizer · NCT00556998 · 26 enrolled · United States
  3. Feb 8, 2008Phase 4 study in AspergillosisPfizer · NCT00620074 · 6 enrolled · United States
  4. Mar 27, 2008Phase 4 study in CandidiasisPfizer · NCT00647907 · 7 enrolled · Taiwan
  5. May 29, 2008Phase 3 study in Candidiasis, InvasivePfizer · NCT00689338 · 216 enrolled · Austria, Belgium, Canada and more
  6. Aug 20, 2008Phase 2 study in CandidiasisPfizer · NCT00739934 · 40 enrolled · United States
  7. Feb 3, 2009Phase 3 study in Invasive AspergillosisPfizer · NCT00836875 · 31 enrolled · United States, Canada, Czechia and more
  8. Mar 2, 2009Phase 1 study in Healthy VolunteersPfizer · NCT00855101 · 35 enrolled · Belgium
  9. Jul 13, 2009Phase 4 study in AspergillosisPfizer · NCT00940017 · 24 enrolled · United States
  10. Mar 10, 2010Phase 3 study in CandidiasisPfizer · NCT01092832 · 23 enrolled · China, Czech Republic, Hong Kong and more
  11. Jun 27, 2011Phase 2 study in AspergillosisPfizer · NCT01383993 · 21 enrolled · Japan
  12. Dec 13, 2015Chong Kun Dang Pharmaceutical's first study: phase 1 study in AspergillosisNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT02631954 · 24 enrolled · Korea, Republic of
  13. Sep 21, 2016Yung Shin Pharm. Ind.'s first study: phase 4 study in MycosesNew to Yung Shin Pharm. Ind.Yung Shin Pharm. Ind. · NCT02912156 · 29 enrolled
  14. Sep 11, 2020Phase 4 study in Antimycotic for Systematic UseYung Shin Pharm. Ind. · NCT04552353 · 14 enrolled · Taiwan

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Cytochrome P450 51 inhibitor”ChEMBL 37, by rule

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT04552353Antimycotic for Systematic Use · Taiwan4CompletedYung Shin Pharm. Ind.Jun 21, 202014
NCT02912156Mycoses4CompletedYung Shin Pharm. Ind.Jul 201629
NCT02631954Aspergillosis · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalOct 201524
NCT01383993Aspergillosis · Japan2CompletedPfizerMay 201321
NCT01092832Candidiasis · China, Czech Republic, Hong Kong and more3TerminatedPfizerMay 201323
NCT00940017Aspergillosis · United States4CompletedPfizerOct 200824
NCT00855101Healthy Volunteers · Belgium1CompletedPfizerJul 200935
NCT00836875Invasive Aspergillosis · United States, Canada, Czechia and more3TerminatedPfizerMay 201331
NCT00739934Candidiasis · United States2CompletedPfizerOct 200940
NCT00689338Candidiasis, Invasive · Austria, Belgium, Canada and more3CompletedPfizerMay 2010216
NCT00647907Candidiasis · Taiwan4CompletedPfizer7
NCT00620074Aspergillosis · United States4TerminatedPfizerFeb 20096
NCT00556998Pharmacokinetics · United States2CompletedPfizerDec 200926
NCT00548262Candidemia · Brazil, Chile, Colombia and more4CompletedPfizerOct 200954
NCT00300677Mycoses · United States4CompletedPfizerAug 200812
NCT00289991Antifungal Prophylaxis of Invasive Fungal Infections · Canada, Czech Republic, Egypt and more3CompletedPfizerFeb 2009489
NCT00288197Invasive Fungal Infections · China4CompletedPfizerJun 200777
NCT00174473Neutropenia2CompletedPfizer49
NCT00159822Aspergillosis · France3CompletedPfizerDec 200848
NCT00150345Neutropenia · Germany3CompletedPfizerApr 2009147
NCT00150319Renal Insufficiency · United States2TerminatedPfizerOct 20051
NCT00143312Invasive Fungal Infections · Belgium, France, Germany and more4CompletedPfizerApr 200845
NCT00136968Mycoses1CompletedPfizer12

How it is read

Names in the registry

  • “Voriconazole”, 13 entries
  • “voriconazole”, 7 entries
  • “voriconazole (Vfend)”, 3 entries
  • “oral voriconazole”, 1 entry
  • “Vaway”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.